Navigation Links
Vista Partners Updates Coverage on Opexa Therapeutics, Inc.; Raises Target Price From $4.40 to $6.50

SAN FRANCISCO, Jan. 6, 2011 /PRNewswire/ -- Vista Partners announced today that it has updated coverage on Opexa Therapeutics, Inc. (Nasdaq: OPXA) and raised its twelve month target price from $4.40 to $6.50. Ross Silver, Principal Analyst at Vista Partners stated, "Opexa announced yesterday that their lead clinical candidate Tovaxin®, an autologous cellular immunotherapy for the treatment of Multiple sclerosis, is now positioned from a regulatory perspective to advance into a pivotal Phase 3 clinical study. In clinical trials performed to date, Tovaxin® has compared favorably to already approved MS therapies, which are multi-billion dollar drugs. Of most significance in our opinion is Tovaxin® ranking ahead of both Copaxone® and Avonex® in Annualized Relapse Rate ("ARR"). ARR is possibly the most clinically relevant endpoint and is the single most important measure by which the FDA evaluates MS drugs for approval." Mr. Silver continued, "Dendreon's Provenge®, the first FDA-approved autologous cellular immunotherapy, has increased awareness and acceptance for this therapeutic approach."

To download a FREE copy of the Opexa Therapeutics, Inc. research report, please visit and complete the research form to gain access to the report.

About Vista Partners:

Vista Partners LLC was founded in 2005 and has offices in California and one in Oregon. We are a Registered Investment Advisor in the States of California and Oregon. Our professional staff has backgrounds in finance, corporate communications and investment banking. Vista Partners has built a name for itself in the small cap space due to its selection of profitable investment ideas.

Disclaimer & Disclosure:

For a full list of disclaimers and disclosures, please visit our website or click here.


877.215.4813 or

SOURCE Vista Partners
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Biovista Announces a Drug Repositioning Collaboration With Pfizer
2. ActiveCare, Inc. Announces Strategic Relationship With Vista Therapeutics, Inc. in Developing Nano Biosensors for the Elderly
3. Novus Biologicals Awards Contract to Biovista Inc. to Drive its Web-Based Novus Explorer Service
4. Biovista Inc. Announces Positive Efficacy Results in a Pre-clinical Trial of its BVA-201 Repositioned Drug for Multiple Sclerosis
5. Vistaar and the Professional Pricing Society Partner to Present Premier Symposium for Pricing Practitioners
6. Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-601 Repositioned Drug for Epilepsy
7. Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-101 Repositioned Drug for Multiple Sclerosis
8. Synvista Therapeutics Announces Restructuring of Dividend Obligation to Preferred Stockholders and Decision to Delist from NYSE Alternext and Terminate SEC Registration of Common Stock
9. Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium
10. Synvista Therapeutics Announces 510(k) Submission for Its HAPTOCHEK(TM) Test Kit
11. Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... ... aesthetic practitioners and aesthetics professionals from Central America and abroad for the first ... Panama City, Panama Feb. 17-19, 2016. Testart will present and discuss new trends ...
(Date:11/30/2015)... -- An interventional radiology technique shows promise for helping morbidly obese ... study being presented today at the annual meeting of the ... --> --> Gastric ... as a way to stop bleeding in emergency situations, but ... treating obesity is new. Mubin Syed , M.D., ...
(Date:11/30/2015)... , Nov. 30, 2015 Harvard ... ), a biotechnology company developing bioengineered organ implants ... written notification from The NASDAQ Stock Market that ... price requirements. The letter noted that as a ... common stock having exceeded $1.00 per share for ...
(Date:11/30/2015)... , Nov. 30, 2015  Champions Oncology, Inc. (CSBR), ... services to personalize the development and use of oncology ... Executive Officer, will be presenting at the LD MICRO ... Pacific Standard Time (PST).  The conference, held at the ... Angeles, CA , will feature 200 small/micro-cap companies ...
Breaking Biology Technology:
(Date:11/9/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), the ... entry into the automotive market with a comprehensive and ... of consumer electronics human interface innovation. Synaptics, industry-leading touch ... the automotive industry and will be implemented in numerous ... , Japan , and ...
(Date:10/29/2015)... 29, 2015 Daon, a global leader in ... released a new version of its IdentityX Platform ... North America have already installed IdentityX v4.0 ... a FIDO UAF certified server component as ... activate FIDO features. These customers include some of the ...
(Date:10/27/2015)... 27, 2015 In the present market scenario, ... for various industry verticals such as banking, healthcare, defense, ... growing demand for secure & simplified access control and ... as hacking of bank accounts, misuse of users, , ... as PC,s, laptops, and smartphones are expected to provide ...
Breaking Biology News(10 mins):